CCL20是与乳腺癌免疫透相关的潜在治疗点
Hongyan Zhai1, Na Zhang1, Dan Mo2
1Department of Oncology, Linfen People's Hospital, Linfen, China.
The Journal of international medical research
|August 12, 2023
概括
化学因子 (C-C动机) 配体20 (CCL20) 在乳腺癌中被上调,与预后不佳和免疫细胞透相关. CCL20可以作为预后生物标志物和治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 化学因子 (C-C 动机) 配体20 (CCL20) 在免疫细胞招募和癌症进展中发挥作用.
- 乳腺癌中CCL20的预后意义尚未得到充分确立.
研究的目的:
- 研究乳腺癌中CCL20表达和临床病理参数之间的相关性.
- 分析CCL20与免疫透和乳腺癌患者预后的关联.
主要方法:
- 使用了TIMER,UALCAN和PrognoScan数据库来评估CCL20表达式.
- 使用GeneMANIA和STING网络构建分析了基因-基因和蛋白质-蛋白质相互作用.
主要成果:
- 在乳腺癌中,CCL20表达显著上调.
- 较高的CCL20表达与不良的临床病理特征和不良预后相关.
- CCL20与各种免疫细胞的透显著相关,包括单细胞,中性粒细胞,TAMs,Th1,Treg和耗尽的T细胞.
结论:
- CCL20是乳腺癌的预后生物标志物,与免疫透水平有关.
- CCL20具有作为乳腺癌治疗点的潜力.
关键词:
CCL20 CCL20 CCL20 CCL20 CCL20 CCL20 CCL20 CCL20 CCL20生物标志物生物标志物乳腺癌 乳腺癌 乳腺癌免疫透 免疫透是什么?互动互动网络互动网络治疗目标是治疗的目标.更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.3K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557